Treatment of early-stage breast cancer with percutaneous thermal ablation, an open-label randomised phase 2 screening trial: rationale and design of the THERMAC trial

Treatment of early-stage breast cancer with percutaneous thermal ablation, an open-label randomised phase 2 screening trial: rationale and design of the THERMAC trial

Introduction Breast cancer is the most frequently diagnosed malignancy worldwide but almost half of the patients have an excellent prognosis with a 5-year survival rate of 98%–99%. These patients could potentially be treated with thermal ablation to avoid surgical excision, reduce treatment-related...

Full description

Bibliographic Details
Main Authors: Erwin Birnie, Cornelis Verhoef, Reno Debets, Taco M A L Klem, Adriaan Moelker, Elles M F van de Voort, Gerson M Struik, Linetta B Koppert, Glenn Yo, Maura J P V Macco, Renata H J A Sinke, Martine Franckena
Format: Article
Language:English
Published: BMJ Publishing Group 2021-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/9/e052992.full

Internet

https://bmjopen.bmj.com/content/11/9/e052992.full

Similar Items